Treatment of familial amyloid polyneuropathy (FAP) using diflunisal

Treatment of familial amyloid polyneuropathy (FAP) using diflunisal - Treatment of FAP using diflunisal

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001825

Enrollment

Registered

2009-03-31

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

familial amyloid polyneuropathy (FAP)

Interventions

Orally administration of diflunisal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: histologically and genetically FAP patients

Exclusion criteria

Exclusion criteria: renal dysfunction pregnancy lactation

Design outcomes

Primary

Measure	Time frame
Clnical FAP scale compound muscle action potential	—

Secondary

Measure	Time frame
cardiac function mBMI	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026